simulation

Digital

Integrating digital twins and virtual trials with AI in clinical research will usher in a new era of drug development for rare diseases.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.